By David Cassak
Three years ago, Rick Randall, CEO of TranS1 Inc. , was wandering around his first North American Spine Society (NASS) meeting. Randall had joined TranS1 just a few months...
TranS1:Transcending the Surgeon/Rep/Relationship
TranS1 is pioneering a radical approach to both fusion and minimally-invasive spine surgery. At the same time, TranS1 is also pioneering a new business model in spine, one that rests on what the company calls "transcending the surgeon/rep relationship."
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
• By
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.